

PIPELINE	Our programs consist of biomarker-driven, small molecule, targeted drug candidates
----------	--

## IN-HOUSE PROGRAMS

DRUG CANDIDATE	INVESTIGATIONAL TARGET(S)	PRE-CLINICAL	PHASE 1	PHASE 2	REGISTRATION TRIAL	FDA APPROVAL
EO-3001 ARID1a Targeted Therapy	Ovaria Clear Cell Carcinoma and Solid Tumors					
EO-4426 (Tezacitabine)	Solid Tumors and Hematologic Malignancies					
Orotecan® (oral irinotecan HCl)	Pediatric Sarcomas and Adult Malignancies					

PARTNERED PROGRAM	Apollomics licensed global rights (ex-China/HK/Taiwan)
-------------------	--



DRUG CANDIDATE	INVESTIGATIONAL TARGET(S)	PRE-CLINICAL	PHASE 1	PHASE 2	REGISTRATION TRIAL	FDA APPROVAL
EO-1001 Pan-ErbB inhibitor	Advanced/metastatic ErbB-positive solid tumors, including EGFR+, NSCLC, HER2+ breast cancer, glioblastoma, and others					

